Jinwon Life Sciences Signs $2 Million Plasmid DNA Drug Supply Contract

[Asia Economy Reporter Jang Hyowon] Jinwon Life Sciences announced on the 8th that it has signed a plasmid DNA pharmaceutical supply contract worth 2 million dollars with a US biotech company.

Jinwon Life Sciences supplies high-quality plasmid DNA pharmaceuticals through its subsidiary VGXI, a US-based cGMP (current Good Manufacturing Practice) contract development and manufacturing organization (CDMO). Currently, a large-scale new facility is being constructed on the production site located in Conroe, Texas, equipped with a quality evaluation laboratory, purification and filling, packaging facilities, raw material warehouses, spaces necessary for process support, as well as offices and convenience facilities.

Park Younggeun, CEO of Jinwon Life Sciences, stated, “VGXI is a global leader in contract manufacturing supplying high-quality plasmids, and we expect steady large-scale supply contracts to be signed this year as well.”